MedTrace Logo

Effect of Metabolaid® on AMPK Activation for Weight Loss

NCT03568877 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-06-27

No results posted yet for this study

Summary

The objective of this study was to establish a formulation, containing both Hibiscus sabdariffa L. (HS) and Lippia citriodora L. (LC) extracts (Metabolaid®) that had significant capacity to activate the AMPK-enzyme and to reduce triglyceride accumulation in the hypertrophied adipocyte model. Then, we assessed the efficacy of this combination in light-to-moderate-overweight subjects under risk of developing metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Metabolaid®

500 mg per day, in fasting conditions.

DIETARY_SUPPLEMENT

Placebo

500 mg per day, in fasting conditions.

Sponsors & Collaborators

  • Monteloeder SL

    collaborator UNKNOWN

  • Universidad Miguel Hernandez de Elche

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
36 Years
Max Age
69 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03568877 on ClinicalTrials.gov